#USA #New York #Pomerantz LLP #Capricor Therapeutics #FDA Review

Pomerantz Law Firm Investigates Claims on Behalf of Capricor Investors

Overview

On June 1, 2025, Pomerantz LLP announced that it is currently investigating potential claims on behalf of investors who purchased shares of Capricor Therapeutics, Inc. (symbol: CAPR). This inquiry is prompted by the company's recent activities and disclosures that may suggest instances of securities fraud or other unlawful business practices. It is crucial for investors to stay informed and aware of their rights as they navigate this situation.

Details of the Investigation

The investigation led by Pomerantz aims to determine whether Capricor's management and certain officers have engaged in misconduct related to the handling of its Biologics License Application (BLA) for an investigational cell therapy called deramiocel, intended to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. On May 5, 2025, Capricor released a press announcement following a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA). The announcement stated that the FDA confirmed its intent to conduct an advisory committee meeting concerning the BLA, raising uncertainties among investors about the drug's approval process.

Impact on Share Price

In the wake of this announcement, Capricor's stock price experienced a significant decline. Specifically, on May 6, 2025, the share price plummeted by $3.00, representing a 29.13% reduction, closing at $7.30. Such drastic changes in stock price can be alarming for investors who rely on accurate and transparent information when making investment decisions.

Pomerantz's Background

Pomerantz LLP is recognized as a leading firm specializing in corporate, securities, and antitrust class litigation with offices in prominent cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. Established by the late Abraham L. Pomerantz, often referred to as the dean of class action bar, the firm has decades of experience advocating for victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. Since its inception over 85 years ago, Pomerantz has successfully secured numerous multimillion-dollar damage awards on behalf of class members.

How to Get Involved

Investors affected by these developments are urged to reach out to Danielle Peyton at Pomerantz LLP to discuss their circumstances. The firm can be contacted via email at [email protected] or by calling 646-581-9980, ext. 7980. Furthermore, additional information about the class action and potential participation can be found on the firm's website.

Conclusion

As the investigation unfolds, it underscores the importance of corporate accountability and the role of law firms in safeguarding investors' rights. It remains essential for stakeholders to keep abreast of developments at Capricor Therapeutics, ensuring they are equipped to make informed decisions about their investments amidst these challenging circumstances. The potential implications of the ongoing investigation may reveal more about corporate practices and provide insights into the future trajectory of Capricor and similar companies in the biotechnology sector.